Intelligent Medical Objects (IMO) Announces Leadership Transition to Support Next Chapter of Growth and Innovation

Intelligent Medical Objects, Inc. (IMO), the market leader in terminology services for healthcare IT serving more than 3,900 hospitals, announced today that Chairman, CEO and Co-Founder Frank Naeymi-Rad, PhD, MS, MBA, will transition from CEO to the new role of Chief Innovator and continue as Chairman of the Board of the company. Ann Barnes, a...

Intelligent Medical Objects, Inc. (IMO), the market leader in terminology services for healthcare IT serving more than 3,900 hospitals, announced today that Chairman, CEO and Co-Founder Frank Naeymi-Rad, PhD, MS, MBA, will transition from CEO to the new role of Chief Innovator and continue as Chairman of the Board of the company. Ann Barnes, a seasoned technology and healthcare executive and former President and CEO of MedData Inc., will assume the role of CEO of IMO effective June 15, 2018.

Since its growth capital investment from Warburg Pincus in 2016, IMO has been on a trajectory of growth and innovation. Sales of its flagship Problem IT® product and the release of the IMO 2.0 innovation platform, together with the evolution of IMO’s industry-leading clinical interface terminology services, have spurred strong business performance. IMO 2.0 unlocked the ability for IMO customers to rapidly innovate on its platform with regular updates that deliver the latest in terminology services and process automation.

“There couldn’t be a better time to have Ann join our leadership team,” said Dr. Naeymi-Rad. “Her vision and experience with health IT solutions supporting provider revenue cycle management align perfectly with our customers’ need to have clinical documentation and transactions integrated with revenue cycle services. The key value that we strive to deliver to all of our customers is transparency in care documentation — the source of “patient truth”. By providing this core value and supporting coding requirements, we help position our Electronic Health Record (EHR) partners for financial growth and stability while supporting our own growth trajectory.”

Ann Barnes joined MedData in 2008, driving the growth and expansion of MedData services to hospitals. Her knowledge and passion for the provider side of the business, as well as her focus on the patient, will be a strong addition to IMO. MedData, a MEDNAX company, provides technology-enabled management solutions for hospitals and health systems that serve the entire patient, payer, and facility financial lifecycle, serving over 10,000 physicians and more than 3,000 facilities nationwide. She is a graduate of the University of the Pacific in California.

“I am looking forward to working together with Frank and the rest of the IMO team to ensure a smooth transition for our company and customers,” said Barnes. “There is an amazing amount of talent here, which we will use to maintain the momentum underway as Frank continues to be a visionary for IMO and the industry in his new role as Chief Innovator.”

IMO’s current phase of growth and innovation has led Dr. Naeymi-Rad to envision initiatives to accelerate the best new ideas in healthcare that use clinical interface terminology to improve the healthcare experience and enable value-based care delivery. “These initiatives align well with our concept of a semantic highway linking all stakeholders in the healthcare ecosystem onto a common terminology standard. I look forward to leading these efforts,” said Dr. Naeymi-Rad.

About Intelligent Medical Objects (IMO)

IMO provides the most widely-accepted medical terminology solution for healthcare organizations worldwide. IMO is the foundational platform for healthcare enterprise needs, from clinical documentation to population health management, and on to the latest in informatics innovation. IMO's terminology is used by more than 3,900 hospitals and 500,000 physicians daily to capture clinical intent and help EHRs preserve and communicate this across the entire spectrum of care. IMO clinical terms are mapped to all standard coding systems including ICD-9, ICD-10 and SNOMED®, and the accuracy of IMO’s interface terminology was found to be “nearly perfect” in an independent study published by the US Centers for Disease Control. In 2016, IMO received a growth capital investment from Warburg Pincus, a global private equity firm focused on growth investing. 

Source: www.businesswire.com